Mostrar registro simples

dc.creatorSchlemmer, Karine Bizzi
dc.date.accessioned2015-03-12
dc.date.available2015-03-12
dc.date.issued2014-03-14
dc.identifier.citationSCHLEMMER, Karine Bizzi. IN VITRO SUSCEPTIBILITY OF Malassezia pachydermatis AGAINST ANTIFUNGAL AGENTS AND ESSENTIAL OIL FRACTIONS. 2014. 139 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.por
dc.identifier.urihttp://repositorio.ufsm.br/handle/1/9007
dc.description.abstractThe yeast Malassezia pachydermatis belongs to the normal microbiota of animals, and is usually implicated as responsible for otitis media and recently by various forms of dermatitis, mainly in dogs. This study aimed to evaluate the in vitro susceptibility of 26 M. pachydermatis isolates against the antifungals fluconazole, itraconazole, ketoconazole, clotrimazole, miconazole, terbinafine and nystatin, and to the combinations of these with thymol, carvacrol and cinnamaldehyde by the checkerboard method, based on document M27-A3. The activity of itraconazol, ketoconazole and clotrimazole against 20 isolates of M. pachydermatis, through simultaneous and sequential exposure of these agents, was also evaluated by the disk-diffusion technique. The minimum inhibitory concentration (MIC) for fluconazole ranged from 1-64 μg/mL, itraconazole 0.01-1 μg/mL, ketoconazole 0.01-0.5 μg/mL, clotrimazole 0.5-32 μg/mL, miconazole 2-32 μg/mL, terbinafine 0.12-32 μg/mL and nystatin 16-64 μg/mL. High rates of synergism were observed in the combinations of nystatin + thymol (88.46%), nystatin + carvacrol (88.46%), nystatin + cinnamaldehyde (73.07%), clotrimazole + thymol (69.23%), clotrimazole + carvacrol (69.23%), miconazole + thymol (65.38%), miconazole + carvacrol (76.92%) and miconazole + cinnamaldehyde (65.38%). However, high rates of indifference were observed in the combinations of fluconazole + thymol (53.84%), carvacrol + fluconazole (46.15%), fluconazole + cinnamaldehyde (65.38%), thymol + itraconazole (61.53%), carvacrol + itraconazole (69.23%), itraconazole + cinnamaldehyde (65.38%), terbinafine + thymol (73.07%), terbinafine + carvacrol (65.38%), terbinafine + cinnamaldehyde (73.07%) and clotrimazole + cinnamaldehyde (61.53%). Ketoconazole combined with thymol, carvacrol and cinnamaldehyde had the highest rates of antagonism (42.3%). The prior exposure of M. pachydermatis to itraconazole resulted in a reduction of the inhibition halo when compared with itraconazole and ketoconazole used simultaneously (p <0.01). Moreover, prior exposure of clotrimazole significantly increased the zone of inhibition (p <0.001) when compared to the simultaneous exposure of itraconazole and clotrimazole. The most significant associations deserve in vivo evaluation in order to verify their potential in the treatment of infections caused by M. pachydermatis.eng
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.formatapplication/pdfpor
dc.languageporpor
dc.publisherUniversidade Federal de Santa Mariapor
dc.rightsAcesso Abertopor
dc.subjectMalassezia pachydermatispor
dc.subjectSuscetibilidadepor
dc.subjectIn vitropor
dc.subjectMalassezia pachydermatiseng
dc.subjectSusceptibilityeng
dc.subjectIn vitroeng
dc.titleSuscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciaispor
dc.title.alternativeIn vitro susceptibility of Malassezia pachydermatis against antifungal agents and essential oil fractionseng
dc.typeDissertaçãopor
dc.description.resumoMalassezia pachydermatis é uma levedura pertencente à microbiota normal de animais e, usualmente, apontada como responsável por otites externas e recentemente por diversas formas de dermatites, principalmente em cães. Este estudo teve como objetivo avaliar a suscetibilidade in vitro de 26 isolados de M. pachydermatis frente aos antifúngicos fluconazol, itraconazol, cetoconazol, clotrimazol, miconazol, terbinafina e nistatina, e combinações desses com timol, carvacrol e cinamaldeído, através do método de checkerboard , baseado no documento M27-A3. Também foram avaliadas a atividade do itraconazol, cetoconazol e clotrimazol, em 20 isolados de M. pachydermatis, através da exposição simultânea e sequencial desses agentes utilizando-se a técnica de disco-difusão. Isoladamente, as concentrações inibitórias mínimas (CIMs) para o fluconazol variaram de 1- 64 μg/mL, para o itraconazol 0,01-1 μg/mL, para o cetoconazol 0,01-0,5 μg/mL, para o clotrimazol 0,5-32 μg/mL, para o miconazol 2-32 μg/mL, para a terbinafina 0,12-32 μg/mL e para a nistatina 16-64 μg/mL. Altas taxas de sinergismo foram observadas nas combinações de nistatina + timol (88,46%), nistatina + carvacrol (88,46%), nistatina + cinamaldeído (73,07%), clotrimazol + timol (69,23%), clotrimazol + carvacrol (69,23%), miconazol + timol (65,38%), miconazol + carvacrol (76,92%) e miconazol + cinamaldeído (65,38%). No entanto, fluconazol + timol (53,84%), fluconazol + carvacrol (46,15%), fluconazol + cinamaldeído (65,38%), itraconazol + timol (61,53%), itraconazol + carvacrol (69,23%), itraconazol + cinamaldeído (65,38%), terbinafina + timol (73,07%), terbinafina + carvacrol (65,38%), terbinafina + cinamaldeído (73,07%) e clotrimazol + cinamaldeído (61,53%) tiveram altas taxas de indiferença. Cetoconazol combinado com timol, carvacrol e cinamaldeído apresentaram as maiores taxas de antagonismo (42,3%). A exposição prévia de M. pachydermatis ao itraconazol resultou em uma diminuição da zona de inibição, quando comparado com o itraconazol e cetoconazol usados simultaneamente (p <0,01). Por outro lado, a exposição prévia do clotrimazol aumentou significativamente a zona de inibição (p <0,001), quando comparado à exposição simultânea de clotrimazol e itraconazol. As associações de maior relevância merecem avaliação in vivo, a fim de verificar o potencial das mesmas no tratamento de infecções por M. pachydermatis.por
dc.contributor.advisor1Santurio, Janio Morais
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/6316012260769979por
dc.contributor.referee1Alves, Sydney Hartz
dc.contributor.referee1Latteshttp://lattes.cnpq.br/0330782478769631por
dc.contributor.referee2Loreto, Érico Silva de
dc.contributor.referee2Latteshttp://lattes.cnpq.br/5475233864057995por
dc.creator.Latteshttp://lattes.cnpq.br/2330632247520007por
dc.publisher.countryBRpor
dc.publisher.departmentFarmacologiapor
dc.publisher.initialsUFSMpor
dc.publisher.programPrograma de Pós-Graduação em Farmacologiapor
dc.subject.cnpqCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIApor


Arquivos deste item

Thumbnail

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples